A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults
Latest Information Update: 27 Jul 2026
At a glance
- Drugs COVID-19 vaccine-Castlevax (Primary) ; COVID-19 vaccine
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors CastleVax
Most Recent Events
- 22 Jul 2026 Planned End Date changed from 19 Aug 2026 to 6 Sep 2026.
- 22 Jul 2026 Planned primary completion date changed from 19 Aug 2026 to 6 Sep 2026.
- 22 Jul 2026 Status changed from recruiting to active, no longer recruiting.